LIFE bioCEEd has announced its investment in the development of a novel therapeutic approach targeting multiple sclerosis (MS), with the potential to fundamentally change the current treatment paradigm. The project originates from the Medical University of Gdańsk and is led by neuroscientist Dr. Aleksandra Rutkowska, whose research focuses on nerve tissue regeneration and the mechanisms underlying neurological damage.

Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system, leading to damage of myelin, the protective sheath surrounding nerve fibres. This results in progressive neurological impairment, including mobility loss, visual disturbances, fatigue, and cognitive decline. Despite advances in treatment, current therapies are limited to slowing disease progression through immunosuppression and do not repair existing damage. This inability to restore nerve tissue remains a key limitation of current MS treatment approaches.

The molecule CF₃-7α,25-OHC represents a novel strategy combining:

• Immunomodulatory effects to reduce pathological immune activity
• Regenerative properties supporting remyelination

Preclinical results have demonstrated both a reduction in inflammation within the central nervous system and indications of myelin regeneration, suggesting potential for both disease control and functional recovery.

LIFE bioCEEd is joining the project at a stage of established preclinical proof of concept and will play a central role in advancing the technology toward clinical application. Key activities include:

• Development of regulatory strategy
• Validation of manufacturing processes
• Preparation of clinical trial protocols
• Coordination of development milestones

The investment is structured as a multi-phase program, with LIFE bioCEEd acting as lead investor and actively supporting both scientific and commercial development.

“This project has the potential to fundamentally shift the treatment of multiple sclerosis towards nerve tissue regeneration,” said Stefan Savic, CEO of LIFE bioCEEd. “It represents the type of scientific innovation we aim to identify and translate into clinical practice.”

Approximately 2.8 million people worldwide are affected by multiple sclerosis, with Europe representing one of the most impacted regions. Despite a global treatment market valued in the tens of billions of euros, no therapy currently enables reliable regeneration of damaged nerve tissue. The supported project aims to address this gap and, if successful in clinical trials, could significantly advance the treatment of MS as well as other neurological disorders associated with myelin damage and chronic inflammation.